Table 1.
Mean ( ± SD) of the size (nm), polydispersity index (PDI), zeta potential (mV) and encapsulation efficiency (%EE) of the liposomal formulations developed in this study.
| Formulation | Size (nm ± SD) | PDI ( ± SD) | Zeta Potential (mV ± SD) | %EE ( ± SD) |
|---|---|---|---|---|
| LUV | 157.53 ± 2.58 | 0.09 ± 0.03 | −19.2 ± 5.5 | – |
| LUV VAN | 152.60 ± 0.80 | 0.17 ± 0.01* | −16.9 ± 0.5 | 32.5 ± 0.1 |
| LUVfuso | 161.87 ± 2.45 | 0.14 ± 0.02 | −48.6 ± 4.9 | – |
| LUVfuso VAN | 153.37 ± 0.70 | 0.20 ± 0.01* | −41.3 ± 2.3* | 11.4 ± 0.1 |
| LUVcat | 130.97 ± 1.59 | 0.13 ± 0.01 | 50.6 ± 3.5 | |
| LUVcat VAN | 139.73 ± 2.55 | 0.18 ± 0.02* | 62.5 ± 5.6* | 10.1 ± 0.1 |
The asterisk “*” indicates statistically significant difference between plain (LUV, LUVFUSO, LUVCAT) and their respective vancomycin-containing liposomes (LUV VAN, LUVFUSO VAN, LUVCAT VAN), p < 0.05 (unpaired t-test).